Why insider trading matters?
When insiders buy shares on the open market, this can thus be regarded as a strong endorsement by those that know the company the best -- they are literally betting their own money on the company's future. Insider selling, however, is not necessarily meaningful in any way, as there is a range of reasons for insiders to liquidate (some) of the shares they own.
Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the phase III clinical trial for the treatment resistant depression and depressive disorders; and phase II/III clinical trials in agitation associated with Alzheimer's disease, as well as completed phase II clinical trial for the treatment of smoking cessation. The company was founded in 2012 and is based in New York, New York.
| Trade Date | Insider | Title | Buy/Sell | #Shares | Price | Value | Option |
|---|---|---|---|---|---|---|---|
| 2020-06-29 | Coleman Mark | Director | Buy | 650 | $78.50 | $51,025 | No |
| 2020-06-29 | Pizzie Nick | Chief Financial Officer | Buy | 777 | $76.64 | $59,549 | No |
| 2019-09-26 | Pizzie Nick | Chief Financial Officer | Buy | 2,180 | $24.80 | $54,064 | No |
| 2019-06-26 | Coleman Mark | Director | Buy | 16,200 | $23.10 | $374,280 | No |
| 2019-06-11 | Pizzie Nick | Chief Financial Officer | Buy | 1,920 | $20.80 | $39,936 | No |
| 2019-05-23 | Saad Mark E | Director | Buy | 3,500 | $22.33 | $78,155 | No |
| 2019-05-13 | Coleman Mark | Director | Buy | 4,650 | $21.44 | $99,696 | No |
| 2019-03-19 | Pizzie Nick | Chief Financial Officer | Buy | 5,400 | $12.58 | $67,939 | No |
| 2019-03-19 | Coleman Mark | Director | Buy | 5,100 | $12.18 | $62,118 | No |
| 2018-06-19 | Pizzie Nick | Chief Financial Officer | Buy | 31,000 | $3.10 | $96,080 | No |
| 2015-12-23 | Kaye Randall | Chief Medical Officer | Buy | 1,000 | $9.03 | $9,026 | No |
Insider Smart
Insider Smart